Amlan® to Present on Biotoxin Control and Antibiotic-Free Poultry Production at Malaysia Livestock 2025 Amlan International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural feed additives, will participate in Malaysia Livestock 2025 at the Kuala Lumpur Convention Centre from August 27–29 CHICAGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amlan International, the animal health business of Oil-Dri® Corporation of America and a global leader in natural feed additives, w ...

São Paulo, Brazil, Aug. 25, 2025 (GLOBE NEWSWIRE) -- GWM officially inaugurated its Brazil Plant in Iracemápolis, São Paulo, marking its first full-process manufacturing hub in South America. With annual production capacity set to grow from 20,000 to 50,000 vehicles, the plant exemplifies GWM’s “high-quality globalization”strategy—delivering global standards while earning local trust.” Industry analysts describe the Brazil Plant as more than a factory, but a symbol of advanced technology, local adaptation, ...

Core Viewpoint - Tevogen Bio Holdings Inc. has reported a significant increase in institutional ownership of its common stock, indicating growing confidence from long-term investors in the company's scientific and operational progress [2][3]. Institutional Ownership Update - As of June 30, 2025, institutional ownership of Tevogen common stock rose by 24% compared to March 31, 2025, following a 60% increase in the first quarter [2]. - The number of institutional holders increased from 51 to 55, with 72% of these holders either increasing or maintaining their positions [2]. Key Contributors - Major contributors to the second quarter growth in institutional ownership were Morgan Stanley and BlackRock, which collectively increased their holdings by 80% [2]. Management Commentary - The Head of Investor Relations at Tevogen stated that the increase in institutional ownership is a positive sign, reflecting the company's scientific advancements and operational milestones, such as positive clinical data and progress towards internal GMP cell manufacturing capabilities [3].

Core Insights - XPO drivers excelled at the 2025 National Truck Driving Championships, showcasing their skills and commitment to safety [1][2] - The competition featured 37 XPO drivers from 24 states, all of whom qualified by winning their state championships and maintaining accident-free records [2] Company Achievements - Jeff Langenhahn secured first place in the Tank Truck class, marking his 12th appearance at nationals with over two million consecutive accident-free miles [5] - Ernie Budlowski achieved second place in the Tank Truck class, also with over two million consecutive accident-free miles, and has participated in nationals 14 times [5] - Jeremy Steger placed second in the 4-Axle class, having been named Grand Champion at the 2025 Wisconsin State Truck Driving Championships [5] - Leroy Williams received the Neill Darmstadter Professional Excellence Award, recognizing his 35 years of service and 15 appearances at the NTDC [5] Company Overview - XPO, Inc. is a leader in asset-based less-than-truckload (LTL) freight transportation in North America, moving 17 billion pounds of freight annually [4] - The company serves 55,000 customers through 608 locations and employs 38,000 people across North America and Europe [4]

Group 1 - NxGen Brands, Inc. is nearing the acquisition of a business in a growing industry sector that could significantly impact its future [1] - The new CEO, Marjorie Schaefer, brings a strong financial background and aims to transform NxGen Brands into a solid company with a global presence [3] - The company is focused on growth and profitability to enhance shareholder value and confidence [2] Group 2 - Marjorie Schaefer emphasizes her commitment to developing new markets and executing a business plan that benefits the company and its shareholders [3] - The company has established a new communication strategy, urging stakeholders to disregard past social media posts and news releases [3] - NxGen Brands will provide updates as it moves in a new direction, with a focus on transparency and shareholder engagement [3]

Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases [4] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [4] Upcoming Investor Conferences - Climb Bio's executive team will participate in several investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 5, 2025, at 10:55 a.m. ET in New York, NY [2] - Baird Global Healthcare Conference on September 9, 2025, at 4:20 p.m. ET in New York, NY [2] - Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, with one-on-one meetings only [2] - Stifel Virtual Immunology and Inflammation Forum on September 16, 2025, at 10:30 a.m. ET, conducted virtually [3] Webcast Information - Live webcasts of the conferences will be accessible via the "Investors and News" section of the Climb Bio website, with replays available approximately two hours after each event and archived for at least 30 days [3]

Core Points - Genentech has commenced construction on its first manufacturing facility on the East Coast, located in Holly Springs, North Carolina, which will support the production of metabolic medicines, including obesity treatments [1][2] - The initial investment for this facility exceeds $700 million and is part of Roche's broader commitment of $50 billion towards US manufacturing infrastructure and R&D [2][8] - The facility is projected to create over 1,900 jobs and is strategically located in a growing biopharmaceutical hub with access to a skilled workforce and leading academic institutions [2][8] - The new site will be completed and operational by 2029, featuring modern biomanufacturing technologies and advanced automation [3] - Designed for high-volume and sustainable production, the facility will enhance Roche's manufacturing capacity and supply chain resilience, complementing existing sites globally [4][8] Company Overview - Roche, founded in 1896, is the world's largest biotechnology company and a leader in in-vitro diagnostics, focusing on developing innovative medicines and diagnostics [5] - Sustainability has been a core aspect of Roche's operations for over 125 years, with commitments to achieve net zero by 2045 [6]

Core Points - Kaldvik AS will hold a presentation of its interim report for Q2 2025 on August 28, 2025, at 09:00 CET [1] - The presentation will be conducted by CEO Vidar Aspehaug and CFO Róbert Róbertsson, and will be available online in English [1] - The interim report will be released on the same day at 07:00 CET [1] Contact Information - CFO Róbert Róbertsson can be reached at +354 843 0086 for any inquiries [2] - The information is disclosed in accordance with Section 5-12 of the Norwegian Securities Trading Act [2]

From the 12V 320Ah Mini to Smart One-Stop Energy Solutions, LiTime Brings Breakthroughs to Users and Continues Its Global Event EngagementsLoveland, Colorado , Aug. 25, 2025 (GLOBE NEWSWIRE) -- LiTime, a global pioneer in new energy technology, showcased its latest lithium battery products featuring four core innovations at Overland Expo MTN West 2025. Looking ahead, LiTime will exhibit at Il Salone del Camper in Italy, the Equip Exposition in the U.S., and other international RV and fishing events, continu ...

Financial Performance - Halmont Properties Corporation reported a net income to shareholders of $9.2 million for the six months ended June 30, 2025, an increase from $7.8 million for the same period in 2024 [1] - Revenue for the six months ended June 30, 2025, was $16.74 million, compared to $15.63 million for the same period in 2024, reflecting a growth of approximately 7.1% [2] - Comprehensive income for common shareholders was $9.40 million for the six months ended June 30, 2025, up from $8.97 million in 2024 [2] Shareholder Metrics - The diluted net income per common share decreased to 3.66 cents in 2025 from 3.85 cents in 2024 [2] - The fully diluted book value of Halmont's common shares increased to 95 cents per share as of June 2025, compared to 84 cents in June 2024 [3] Investments and Operations - The financial results reflect contributions from investments made in 2024, including the repositioning of commercial property and forest portfolios [2] - Notable acquisitions included interests in 25 Dockside Drive and 2 Queen East, along with a $1.0 million investment in Haliburton Forest, raising effective ownership to 59% [2]